A successful intellectual property strategy always complies with regulatory rules and laws
We are experts in navigating the complex Canadian regulatory environment.
In the strict and constantly changing regulatory environment for pharmaceuticals and biologics in Canada, expert regulatory and compliance advice and counselling is essential to maximize commercial opportunities while minimizing unnecessary risk.
Drawing on our extensive legal and litigation expertise in regulatory areas, we provide an integrated team approach and a level of technical depth and support for our Canadian and international clients that is unmatched in Canada.
Our lawyers have deep expertise in managing issues that arise at the pharmaceutical/biologic patent-regulatory interface. We offer our clients expert assistance and targeted advice, helping to develop and implement policies to ensure best practices. We also have extensive experience drafting submissions on proposed regulatory amendments. In addition, if necessary, our experienced litigators will pursue judicial reviews before federal, provincial and appellate courts.
We recognize the importance of coordinating patent prosecution and enforcement with regulatory and market status of pharmaceutical and biologic drug products, throughout a product’s life cycle, from early clinical development to regulatory approval to litigation and beyond.
In our regulatory and compliance practice we work with and advise clients on matters that extend to and include pharmaceuticals (small molecules), biologics, Advanced Therapeutic Products, controlled drugs and substances, medical devices, natural health products and veterinary products.
Our regulatory and compliance services include:
- Regulatory (Health Canada and provincial) and health care compliance advice
- Reimbursement, interchangeability, rebate and procurement advice
- Marketing and advertising, including programs with HCPs and patients, disease awareness initiatives, collaboration agreements, PR communications, Direct-to-Consumer advertising campaigns, and Innovative Medicines Canada (IMC) and Pharmaceutical Advertising Advisory Board (PAAB) matters
- Brand name assessments including Look-alike Sound-alike (LA/SA) Assessments of product names
- Access to Information Act and Freedom of Information and Protection of Privacy Act matters
- Regulatory due diligence
- Data protection advice and responding to eligibility rejections by the Office of Patented Medicines and Liaison (OPML)
- Patent listing under the Patented Medicines (Notice of Compliance) Regulations, including preparation of forms and responding to objections by the OPML
- Certificates of supplementary protection, including preparation of applications
- Patented Medicine Prices Review Board (PMPRB) advice
- Submissions on draft statutory and regulatory amendments
- Applications for judicial review
We assist our clients with all relevant government agencies, including:
- Health Canada
- Patented Medicine Prices Review Board
- Provincial insurers
- Regulatory colleges for health care professionals
- The Office of Patented Medicines and Liaison
We advise on all applicable legislation, including:
- The Food and Drugs Act
- Provincial reimbursement (e.g. Ontario Drug Benefit Act, Drug Interchangeability and Dispensing Fee Act)
- Laws governing health care professionals (e.g. Medicine Act, Drug and Pharmacies Regulation Act)
- Access to Information Act
- Freedom of Information and Protection of Privacy Act
Key Contacts
Unparalleled Expertise in Life Sciences Regulatory & Compliance
-
Lexpert
19 Lexpert®-ranked lawyers
2022-2023Lexpert Special Edition: Technology and Health Sciences -
Who's Who Legal
Four Life Sciences leaders
2023Who's Who Legal: Life Sciences -
Who's Who Legal
Six Thought Leaders in Patents, Trademarks & Life Sciences
2023WWL Thought Leaders: Global Elite -
Who's Who Legal
16 leading IP experts
2022Who's Who Legal: Canada -
Who's Who Legal
17 leading IP experts
2022Who's Who Legal: IP -
Who's Who Legal
Five Life Sciences leaders
2018-2022Who's Who Legal: Life Sciences -
Who's Who Legal
Four Thought Leaders in Patents and Trademarks
2022WWL Thought Leaders: Global Elite -
Who's Who Legal
17 leading IP experts
2020-2021Who's Who Legal: Canada -
Who's Who Legal
17 leading IP experts
2021Who's Who Legal: IP -
Lexpert
Nine Lexpert®-ranked lawyers
2021Lexpert Special Edition: Health Sciences
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal relating to Minister of Health’s decision to disclose records pursuant to Access to Information Act request
On November 1, 2023, the Federal Court of Appeal (FCA) dismissed Actial’s appeal from an application for judicial review of the Minister of Health’s decision to disclose records pursuant to a request...Read More -
FCA dismisses appeal, patent not listable against STELARA SNDS
On November 21, 2023, the Federal Court of Appeal (FCA) dismissed Janssen’s appeal: Janssen Inc v Canada (Health), 2023 FCA 229.Read More -
Supreme Court of Canada agrees to hear challenge to “multi-Crown” class actions under the BC Opioid Damages and Health Care Costs Recovery Act
The Supreme Court of Canada has granted Sanis Health, Shoppers Drug Mart, Sandoz Canada, and McKesson Canada leave to appeal Sandoz Canada v British Columbia, 2023 BCCA 306.Read More -
Federal Court finds no procedural unfairness in Minister of Health’s decision that smoking cessation aid not a natural health product
On November 2, 2023, the Federal Court dismissed The Winning Combination (TWC)’s application for judicial review of Health Canada’s decision to refuse a natural health product licence for RESOLVE, a s...Read More -
Medical Devices updates: Annual performance report, new guiding principles for PCCPs for machine learning-enabled medical devices, and regulatory enrolment processes
Explore the latest updates in the field of medical devices, including Health Canada's recently published annual report detailing metrics on the timeliness of pre-market medical device reviews.Read More -
Minister of Health announces Advisory Group and three-year consultation period for the National Strategy for Drugs for Rare Diseases
On October 30, 2023, the Minister of Health announced the creation of the Implementation Advisory Group (IAG) for drugs for rare diseases.Read More -
Federal Court of Appeal and Federal Court release three decisions relating to macitentan (Janssen’s OPSUMIT)
Apotex appealed the trial decision, finding that Apo-Macitentan would infringe Canadian Patent No. 2,659,770 (770 Patent).Read More -
PMPRB publishes scoping paper for consultation on guidelines and invites stakeholder feedback
The Patented Medicine Prices Review Board announced that it will launch the first phase of consultations on new guidelines. On November 10, 2023, the PMPRB published its Scoping Paper for the Consulta...Read More
Related News & Media
-
BIO 2023: Connect with Smart & Biggar’s leading Canadian Life Sciences team
Smart & Biggar's leading Life Sciences team will be attending this year’s Bio International Convention in Boston, and look forward to reconnecting with colleagues and clients from around the world...Read More -
Smart & Biggar sees four lawyers recognized in Who’s Who Legal: Life Sciences 2023
Smart & Biggar is proud to announce that four lawyers have been named in the recent Who’s Who Legal: Life Sciences 2023 Global Guide as leaders in life sciences law.Read More -
Smart & Biggar boasts 16 lawyers and agents recognized as leaders for IP in Who’s Who Legal: Canada Guide 2022
Smart & Biggar is proud to be featured once again as a leader in IP in the recent edition of Who’s Who Legal (WWL) Canada Guide 2022. In total, 16 of our lawyers and patent agents have been recogn...Read More -
Smart & Biggar partners recognized in the 2022 edition of IAM Strategy 300: The World’s Leading IP Strategists
Smart & Biggar is proud to share that Ottawa partner and Chair of the firm Daphne Lainson and Montréal partner Sanjay Goorachurn have been recognized once again in the 2022 edition of IAM Strategy...Read More -
Smart & Biggar partners recognized at the 10th annual LMG Life Sciences Awards Americas 2022
Smart & Biggar is proud to share that Ottawa partner and Chair of the firm Daphne Lainson and Vancouver partner Mark Pidkowich have been recognized in the 10th annual LMG Life Sciences Awards Amer...Read More -
Smart & Biggar receives six shortlist nominations for the 2022 LMG Life Sciences Americas Awards
Smart & Biggar is proud to announce that we have been shortlisted for six LMG Life Sciences Awards 2022. Each award nomination recognizes Smart & Biggar’s exceptional leadership in life scien...Read More -
Smart & Biggar leads the Canadian patent rankings with 23 lawyers and agents listed in IAM Patent 1000
Smart & Biggar is pleased to announce our continued standing as a ‘gold tier' firm in Canada for patent prosecution and litigation, in the 2022 IAM Patent 1000: The World’s Leading Patent Professi...Read More -
Smart & Biggar stands out with 19 lawyers featured as industry leaders in Lexpert Special Edition: Technology and Health Sciences 2022
Smart & Biggar is pleased to share that 19 of our lawyers have been listed in this year’s Lexpert Special Edition: Technology and Health Sciences 2022 as industry leaders.Read More